| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Genitourinary Imaging |
1 From the Renal Unit (T.A.C., P.C.T., S.T.W.M., K.S.) and Radiology Department (G.H.R.), Glasgow Royal Infirmary, Castle Street, 3rd Floor Walton Bldg, Glasgow G4 0SF, Scotland; and Renal Unit, Level 7, Western Infirmary, Glasgow, Scotland (P.B.M., J.P.T., A.G.J.). Received February 20, 2007; revision requested March 20; revision received April 2; accepted April 16; final version accepted May 2. Address correspondence to P.C.T. (e-mail: peter.thomson{at}northglasgow.scot.nhs.uk).
Purpose: To retrospectively compare the frequency of administration and cumulative dose of gadolinium-based contrast agent in dialysis-dependent patients who did and those who did not develop nephrogenic systemic fibrosis.
Materials and Methods: The ethics committees granted exempt status for this study and also waived the need for informed consent. A retrospective analysis was performed of all adult patients undergoing dialysis in the west of Scotland between January 1, 2000, and July 1, 2006. Diagnoses of nephrogenic systemic fibrosis, episodes of gadolinium-enhanced magnetic resonance (MR) imaging, and cumulative doses of gadolinium-based contrast agent were recorded. Outcomes were analyzed by means of parametric and nonparametric testing.
Results: Fourteen of 1826 patients had a diagnosis of nephrogenic systemic fibrosis. Mortality was similar for affected and nonaffected patients. Thirteen (93%) of 14 patients with nephrogenic systemic fibrosis had undergone gadolinium-enhanced MR imaging compared with 408 (22.5%) of 1812 nonaffected patients (P < .001). Patients with nephrogenic systemic fibrosis received a higher median cumulative dose of gadodiamide (0.39 vs 0.23 mmol per kilogram of body weight, P = .008) and underwent more gadolinium-enhanced MR imaging than their nonaffected gadolinium-exposed counterparts.
Conclusion: The data support a positive association between gadolinium-based contrast agent administration and development of nephrogenic systemic fibrosis in the established renal failure population; in addition, there is a positive association between cumulative dose of gadodiamide used and dosing events.
© RSNA, 2007
This article has been cited by other articles:
|
|
 |
|
  A. Tomasian, N. Salamon, D. G. Lohan, M. Jalili, J. P. Villablanca, and J. P. Finn Supraaortic Arteries: Contrast Material Dose Reduction at 3.0-T High-Spatial-Resolution MR Angiography--Feasibility Study Radiology, December 1, 2008; 249(3): 980 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Kuo NSF-Active and NSF-Inert Species of Gadolinium: Mechanistic and Clinical Implications Am. J. Roentgenol., December 1, 2008; 191(6): 1861 - 1863. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Agarwal, S. M. Brunelli, K. Williams, M. D. Mitchell, H. I. Feldman, and C. A. Umscheid Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis Nephrol. Dial. Transplant., October 24, 2008; (2008) gfn593v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Weinreb Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? Radiology, October 1, 2008; 249(1): 3 - 8. [Full Text] [PDF]
|
|
|
|
|
|
F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman, J. Silberzweig, R. L. DeLapaz, H. J. Lee, C. M. Magro, and A. M. Valeri Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers Radiology, September 1, 2008; 248(3): 807 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wertman, , BA, E. Altun, D. R. Martin, D. G. Mitchell, J. R. Leyendecker, R. B. O'Malley, D. J. Parsons, E. R. Fuller III, and R. C. Semelka Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities Radiology, September 1, 2008; 248(3): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Lansberg, V. N. Thijs, R. Bammer, J.-M. Olivot, M. P. Marks, L. R. Wechsler, S. Kemp, and G. W. Albers The MRA-DWI Mismatch Identifies Patients With Stroke Who Are Likely to Benefit From Reperfusion Stroke, September 1, 2008; 39(9): 2491 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Rofsky, A. D. Sherry, and R. E. Lenkinski Nephrogenic Systemic Fibrosis: A Chemical Perspective Radiology, June 1, 2008; 247(3): 608 - 612. [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsushima, A. Takahashi-Taketomi, and K. Endo Nephrogenic Systemic Fibrosis in Japan: Advisability of Keeping the Administered Dose as Low as Possible Radiology, June 1, 2008; 247(3): 915 - 916. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Perazella How Should Nephrologists Approach Gadolinium-based Contrast Imaging in Patients with Kidney Disease? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 649 - 651. [Full Text] [PDF]
|
|
|
|
 |
|
 L R Williams, M J Oldale, and A J Bradley Imaging renal masses and staging renal tumours Imaging, March 1, 2008; 20(1): 73 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Shabana, R. H. Cohan, J. H. Ellis, H. K. Hussain, I. R. Francis, L. D. Su, S. K. Mukherji, and R. D. Swartz Nephrogenic Systemic Fibrosis: A Report of 29 Cases Am. J. Roentgenol., March 1, 2008; 190(3): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kahana, M. J. Lucarelli, A. M. Grayev, J. J. Van Buren, C. N. Burkat, and L. R. Gentry Noninvasive Dynamic Magnetic Resonance Angiography With Time-Resolved Imaging of Contrast KineticS (TRICKS) in the Evaluation of Orbital Vascular Lesions Arch Ophthalmol, December 1, 2007; 125(12): 1635 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Nephrogenic Systemic Fibrosis: A Presumed Complication of Gadolinium-Enhanced MRI Journal Watch (General), October 16, 2007; 2007(1016): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
